Discovery and therapeutic promise of selective androgen receptor modulators

Molecular Interventions

Volumn 5, Issue 3, 2005, Pages 173-188

  Chen, Jiyun ^a,c   Kim, Juhyun ^a,d   Dalton, James T ^a,b,e  

^a OHIO STATE UNIVERSITY   (United States)

^b 2GTx Inc   (United States)

^c AMGEN INC   (United States)

^d Chosun University   (South Korea)

^e GTx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; FINASTERIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR AFFECTING AGENT; HYDANTOIN DERIVATIVE; HYDROXYFLUTAMIDE; PROPIONAMIDE DERIVATIVE; QUINOLINE DERIVATIVE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ACNE; ANDROGEN DEFICIENCY; BODY COMPOSITION; BODY WEIGHT; BONE MASS; CHOLESTEROL BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG STRUCTURE; GYNECOMASTIA; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; MOLECULAR MODEL; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE MASS; OSTEOPOROSIS; PHARMACOPHORE; PROSTATE HYPERTROPHY; RASH; REVIEW; SKIN IRRITATION; SPERMATOGENESIS; STRUCTURE ACTIVITY RELATION;

ANDROGENS; ANIMALS; DRUG DESIGN; HORMONE ANTAGONISTS; HUMANS; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 22544467523     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.5.3.7     Document Type: Review

References (95)

1. Mooradian, A.D., Morley, J.E., and Korenman, S.G. Biological actions of androgens. Endocr. Rev. 8, 1-28 (1987).
2. Hijazi, R.A. and Cunningham, G.R. Andropause: Is androgen replacement therapy indicated for the aging male? Annu. Rev. Med. 56, 117-137 (2005).
3. Kamischke, A. and Nieschlag, E. Progress towards hormonal male contraception. Trends Pharmacol. Sci. 25, 49-57 (2004). An excellent review of hormonal male contraception and its future direction.
4. Vale, W., Wiater, E., Gray, P., Harrison, C., Bilezikjian, L., and Choe, S. 2004 Activins and inhibins and their signaling. Ann. N.Y. Acad. Sci. 1038, 142-147 (2004).
5. McLachlan, R.I. The endocrine control of spermatogenesis. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 14, 345-362 (2000).
6. Manolagas, S.C., Kousteni, S., and Jilka, R.L. Sex steroids and bone. Recent Prog. Horm. Res. 57, 385-409 (2002).
7. Kousteni, S., Chen, J.R., Bellido, T. et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298, 843-846 (2002).
8. Hofbauer, L.C. and Khosla, S. 1999 Androgen effects on bone metabolism: Recent progress and controversies. Eur. J. Endocrinol. 140, 271-286 (1999).
9. Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M.K., Bouillon, R., and Ohlsson, C. Androgens and bone. Endocr. Rev. 25, 389-425 (2004)
10. Huber, D.M., Bendixen, A.C., Pathrose, P., Srivastava, S., Dienger, K.M., Shevde, N.K., and Pike, J.W. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 142, 3800-3808 (2001).
11. Ferrando, A., Sheffield-Moore, M., Yeckel, C. et al. Testosterone administration to older men improves muscle function: Molecular and physiological mechanisms. Am. J. Physiol. Endocrinol. Metab. 282, E601-E607 (2002).
12. Brodsky, I., Balagopal, P., and Nair, K. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - a clinical research center study. J. Clin. Endocrinol. Metab. 81, 3469-3475 (1996).
13. Bhasin, S. Testosterone supplementation for aging-associated sarcopenia. J. Gerontol. A Biol. Sci. Med. Sci. 58, 1002-1008 (2003).
14. Taylor, W., Bhasin, S., Singh, R., Artaza, J., Gonzalez-Cadavid, N. Testosteorone promotes myogenesis in pluripotent mesenchymal cells. Endocrine Society National Abstracts 84th Annual Meeting, 432 (2002).
15. Liao, S., Liang, T., Fang, S., Castaneda, E., and Shao, T.C. Steroid structure and androgenic activity. Specificities involved in the receptor binding and nuclear retention of various androgens. J. Biol. Chem. 248, 6154-6162 (1973).
16. Andriole, G., Bruchovsky, N., Chung, L.W., Matsumoto, A.M., Rittmaster, R., Roehrborn, C., Russell, D., and Tindall, D. Dihydrotestosterone and the prostate: The scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J. Urol. 172, 1399-1403 (2004).
17. Lowe, F.C., McConnell, J.D., Hudson, P.B. et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 61, 791-796 (2003).
18. Shibata, Y., Ito, K., Suzuki, K., Nakano, K., Fukabori, Y., Suzuki, R., Kawabe, Y., Honma, S., Yamanaka, H. Changes in the endocrine environment of the human prostate transition zone with aging: Simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 42, 45-55 (2000).
19. Castagnetta, L.A., Miceli, M.D., Sorci, C.M., Pfeffer, U., Farruggio, R., Oliveri, G., Calabro, M., and Carruba, G. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 136, 2309-2319 (1995).
20. Bhasin, S. and Bremner, W.J. Clinical review 85: Emerging issues in androgen replacement therapy. J. Clin. Endocrinol. Metab. 82, 3-8 (1997).
21. Gronemeyer, H., Gustafsson, J.A., and Laudet, V. Principles for modu-lation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3, 950-964 (2004). An excellent review of nuclear hormone receptor structures and function, with an emphasis on the molecular mechanisms of tissue selectivity.
22. Riggs, B.L. and Hartmann, L.C. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N. Engl. J. Med. 348, 618-629 (2003).
23. Kumar, N., Didolkar, A.K., Monder, C., Bardin, C.W., and Sundaram, K. The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 130, 3677-3683 (1992).
24. Dalton, J.T., Mukherjee, A., Zhu, Z., Kirkovsky, L., and Miller, D.D. Discovery of nonsteroidal androgens. Biochem. Biophys. Res. Commun. 244, 1-4 (1998). The first report to show that a nonsteroidal antagonist could be successfully converted to an androgen agonist.
25. Edwards, J.P., West, S.J., Pooley, C.L., Marschke, K.B., Farmer, L.J., and Jones, T.K. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg. Med. Chem. Lett. 8, 745-750 (1998).
26. Higuchi, R.I., Edwards, J.P., Caferro, T.R. et al. 4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: Potent, nonsteroidal androgen receptor agonists. Bioorg. Med. Chem. Lett. 9, 1335-1340 (1999).
27. Zhi, L., Tegley, C.M., Marschke, K.B., and Jones, T.K. Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone. Bioorg. Med. Chem. Lett. 9, 1009-1012 (1999).
28. Lambert, R.W. Royal Society of Chemistry (Great Britain). Fine Chemicals and Medicinals Group. Society of Chemical Industry (Great Britain). Fine Chemicals Group. 1986 Third SCI-RSC Medicinal Chemistry Symposium: The proceedings of a symposium organised by the Fine Chemicals and Medicinals Group of the Industrial Division of the Royal Society of Chemistry and the Fine Chemicals Group of the Society of Chemical Industry, Cambridge, England, 15-18 September 1985. Royal Society of Chemistry, London
29. Tucker, H., Crook, J.W., and Chesterson, G.J. Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J. Med. Chem. 31, 954-959 (1998).
30. Yin, D., He, Y., Perera, M.A., Hong, S.S., Marhefka, C., Stourman, N., Kirkovsky, L., Miller, D.D., and Dalton, J.T. Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol. Pharmacol. 63, 211-223 (2003).
31. Kirkovsky, L., Mukherjee, A., Yin, D., Dalton, J.T., and Miller, D.D. Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring. J. Med. Chem. 43, 581-590 (2000).
32. Yin, D., Xu, H., He, Y., Kirkovsky, L.I., Miller, D.D., and Dalton, J.T. Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J. Pharmacol. Exp. Ther. 304, 1323-1333 (2003).
33. Yin, D., Gao, W., Kearbey, J.D. et al. Pharmacodynamics of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. 304, 1334-1340 (2003). The first report of the tissue-selective pharmacologic activity of a SARM in castrated rats.
34. Marhefka, C.A., Gao, W., Chung, K., Kim, J., He, Y., Yin, D., Bohl, C., Dalton, J.T., and Miller, D.D. Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J. Med. Chem. 47, 993-998 (2004).
35. Kim, J., Wu, D., Hwang, D.-J., Miller, D.D., and Dalton, J.T. The 4-para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl- phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. in press (2005).
36. Chen, J., Hwang, D.J., Bohl, C.E., Miller, D.D., and Dalton, J.T. A selective androgen receptor modulator for hormonal male contraception. J. Pharmacol. Exp. Ther. 312, 546-553 (2005). The first report to demonstrate the potential of an orally bioavailable SARM for hormonal male contraception.
37. Fisher, S., Hong, S.-S., Miller, D.D., and Dalton, J.T. Preclinical pharmacology and pharmacokinetics of a novel A-ring substituted selective androgen receptor modulator (sarm) in rats. AAPS J. 6, T2256 (2004).
38. Kearbey, J.D., Wu, D., Gao, W., Miller, D.D., and Dalton, J.T. Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. Xenobiotica 34, 273-280 (2004).
39. Gao, W., Veverka, K.A., Chung, K., Miller, D.D., Dalton, J.T. Species difference in the metabolism of selective androgen receptor modulators (sarms). AAPS J. 5, T3336 (2003).
40. Chen, J., Xiao, J., Chung, K., Miller, D.D., and Dalton, J.T. Preclinical pharmacology, pharmacokinetics, and metabolism of a novel selective androgen receptor modulator (sarm) in male rats. AAPS J. 6, W5299 (2004).
41. Wu, D., Wu, Z., Nair, V., Miller, D.D., and Dalton, J.T. Urinary metabolites of S-1, a novel selective androgen receptor modulator (sarm), in rats. AAPS J. 6, W5300 (2004).
42. Marhefka, C.A., Moore, B.M., 2nd, Bishop, T.C., Kirkovsky, L., Mukherjee, A., Dalton, J.T., and Miller, D.D. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J. Med. Chem. 44, 1729-1740 (2001).
43. Bohl, C.E., Chang, C., Mohler, M.L., Chen, J., Miller, D.D., Swaan PW, and Dalton, J.T. A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J. Med. Chem. 47, 3765-3776 (2004).
44. Bohl ,C.E., Gao, W., Miller, D.D., Bell, C.E., and Dalton, J.T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 102, 6201-6206 (2005). An important paper showing the unique interaction of a nonsteroidal antiandrogen with the androgen receptor.
45. Sack, J.S., Kish, K.F., Wang, C. et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 98, 4904-4909 (2001).
46. Bhasin, S., Storer, T., Berman, N., Yarasheski, K., Clevenger, B., Phillips, J., Lee, W., Bunnell, T., and Casaburi, R. Testosterone replacement increases fat-free mass and muscle size in hypogonal men. J. Clin. Endocrinol. Metab. 82, 407-413 (1997).
47. Bhasin, S., Storer, T., Berman, N. et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med. 335, 1-7 (1996).
48. Kenny, A., Prestwood, K., Gruman, C., Marcello, K., and Raisz, L. Effects of transdermal testosterone on bone and muscle in older men with low bioabailable testosterone levels. J. Gerontol. 56, M266-M272 (2001).
49. Sih, R., Morely, J., Kaiser, F., Perry, H., Patrick, P., and Ross C. Testosterone replacement in older hypogonadal men: A 12 month randomized, controlled trial. J. Clin. Endocrinol. Metab. 82, 1661-1667 (1997).
50. Snyder, P., Peachey, H., Hannoush, P. et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endrocrinol. Metab. 84, 2646-2653 (1999).
51. Storer, T., Magliano, L., Woodhouse, L., Casaburi, R., and Bhasin, S. Testosterone dose-dependently increases muscle strength and leg power, but not specific tension in healthy, young men. J. Clin. Endocrinol. Met. 88, 1478-1485 (2003).
52. Amory, J., Chansky, H., Chansky, K., Camuso, M., Hoey, C., Anawalt, B., Matsumoto, A., Bremner, W. Preoperative supraphysiological testosterone in older men undergoing knee replacement surgery. JAGS 50, 1698-1701 (2002).
53. Crawford, B., Lie, P., Kean, M., Bleasel, J., and Handelsman, D. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long tern systemic glucocorticoid treatment. J. Clin. Endocrinol. Metab. 88, 3167-3176 (2003).
54. Gao, W., Reiser, P.J., Kearbey, J.D., Phelps, M.A., Coss, C.C., Miller, D.D., and Dalton, J.T. Effects of a novel selective androgen receptor modulator (SARM) on skeletal muscle mass and strength in castrated male ats. The Endocrine Society, New Orleans, P2-120, June 2004.
55. Gao, W. J. RP, Kearbey, J.D., Phelps, M.A., Coss, C.C., Miller, D.D., Dalton, J.T. Effects of a novel selective androgen receptor modulator (SARM) on skeletal muscle mass and strength in castrated male rats. The Endocrine Society's 86th Annual Meeting: P2-120 (2004).
56. Boonen, S., Vanderschueren, D., Cheng, X.G., Verbeke, G., Dequeker, J., Geusens, P., Broos, P., and Bouillon, R. Age-related (type II) femoral neck osteoporosis in men: Biochemical evidence for both hypovitaminosis D- and androgen deficiency-induced bone resorption. J. Bone Miner. Res. 12, 2119-2126 (1997).
57. Daniell, H.W. Osteoporosis after orchidectomy for prostate cancer. J. Urol. 157, 439-444 (1997).
58. Leifke, E., Korner, H.C., Link, T.M., Behre, H.M., Peters, P.E., and Nieschlag, E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur. J. Endocrinol. 138, 51-58 (1998).
59. Gregoriou, O., Kouskouni, E., Bakas, P., Konidaris, S., Papadias, K., Kalovidouris, A., and Creatsas, G. Bone mineral density in women with idiopathic hirsutism. Gynecol. Endocrinol. 14, 364-368 (2000).
60. Notelovitz, M. Androgen effects on bone and muscle. Fertil. Steril. 77(Suppl. 4), S34-S41 (2002).
61. Soule, S.G., Conway, G., Prelevic, G.M., Prentice, M., Ginsburg, J., and Jacob, H.S. Osteopenia as a feature of the androgen insensitivity syndrome. Clin. Endocrinol. 43, 671-675 (1995).
62. Wakley, G.K., Schutte, H.D.J., and Hannon, K.S. Androgen treatment prevents loss of cancellous bone in the orchidectomized rat. J. Bone Miner. Res. 6, 325-330 (1991).
63. Mason, R.A. and Morris, H.A. Effects of dihydrotestosterone on bone biochemical markers in sham and oophorectomized rats. J. Bone Miner. Res. 12, 1431-1437 (1997).
64. Goulding, A. and Gold, E. Flutamide-mediated androgen blockade evokes osteopenia in the female rat. J. Bone Miner. Res. 8, 763-769 (1993).
65. Hanada, K., Furuya, K., Yamamoto, N. et al. Bone anabolic effects of S-40543, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol. Pharm. Bull. 26, 1563-1569 (2003). The first report of the tetrahydroquinoline-based SARMs and the effects of a SARM on bone.
66. Rosen, J. and Negro-Vilar, A. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J. Musculoskelet. Neuronal Interact. 2, 222-224 (2002). A brief perspective article outlining the potential therapeutic applications of SARMs.
67. Kearbey, J.D., Gao, W., Miller, D.D., and Dalton, J.T. Selective androgen receptor modulators inhibit bone resorption in rats. Pharm. Sci. 5, R61-R67 (2003).
68. Orwoll, E.S. Androgens as anabolic agents for bone. Trends Endocrinol. Metab. 7, 77-84 (1996).
69. Turner, R.T., Wakley, G.K., and Hannon, K.S. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J. Orthop. Res. 8, 612-617 (1990).
70. Compston, J.E. Sex steroids and bone. Physiol. Rev. 81, 419-447 (2001).
71. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet 336, 955-959 (1990).
72. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil. Steril. 65, 821-829 (1996). The article and the one above it are the first two proof-of-concept studies to use testosterone for hormonal male contraception.
73. Gu, Y.Q., Wang, X.H., Xu, D., Peng, L., Cheng, L.F., Huang, M.K., Huang, Z.J., and Zhang, G.Y. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J. Clin. Endocrinol. Metab. 88, 562-568 (2003).
74. Wallace, E.M., Gow, S.M., and Wu, F.C. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations. J. Clin. Endocrinol. Metab. 77, 290-293 (1993).
75. Anderson, R.A., Wallace, A.M., and Wu, F.C. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. J. Clin. Endocrinol. Metab. 81, 902-908 (1996).
76. Behre, H.M., Baus, S., Kliesch, S., Keck, C., Simoni, M., and Nieschlag, E. Potential of testosterone buciclate for male contraception: Endocrine differences between responders and nonresponders. J. Clin. Endocrinol. Metab. 80, 2394-2403 (1995).
77. Handelsman, D.J., Farley, T.M., Peregoudov, A., and Waites, G.M. Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil. Steril. 63, 125-133 (1995).
78. Eckardstein, S.V., Schmidt, A., Kamischke, A., Simoni, M., Gromoll, J., and Nieschlag, E. CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin. Endocrinol. (Oxf.) 57, 647-655 (2002).
79. Prasad, M.R. and Rajalakshmi, M. Target sites for suppressing fertility in the male. Adv. Sex Horm. Res. 2, 263-287 (1976).
80. Wang, C. and Swerdloff, R.S. Male hormonal contraception. Am. J. Obstet. Gynecol. 190, S60-S68 (2004).
81. Hair, W.M., Kitteridge, K., O'Connor, D.B., and Wu, F.C. A novel male contraceptive pill-patch combination: Oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. J. Clin. Endocrinol. Metab. 86, 5201-5209 (2001).
82. Turner, L., Conway, A.J., Jimenez, M., Liu, P.Y., Forbes, E., McLachlan, R.I., and Handelsman, D.J. Contraceptive efficacy of a depot progestin and androgen combination in men. J. Clin. Endocrinol. Metab. 88, 4659-4667 (2003).
83. Hay, .CJ., Brady, B.M., Zitzmann, M. et al. A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. J. Clin. Endocrinol. Metab. 90, 2042-2049 (2005).
84. Ramachandra, S.G., Ramesh, V., Krishnamurthy, H.N., Kumar, N., Sundaram. K, Hardy, M.P., and Rao, A.J. Effect of chronic administration of 7alpha-methyl-19-nortestosterone on serum testosterone, number of spermatozoa and fertility in adult male bonnet monkeys (Macaca radiata). Reproduction 124, 301-309 (2002).
85. von Eckardstein S, Noe G, Brache V et al. A clinical trial of 7 alphamethyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J. Clin. Endocrinol. Metab. 88, 5232-5239 (2003). The first clinical study using MENT for hormonal male contraception.
86. Cummings, D.E., Kumar, N., Bardin, C.W., Sundaram, K., and Bremner, W.J. Prostate-sparing effects in primates of the potent androgen 7alphamethyl-19- nortestosterone: A potential alternative to testosterone for androgen replacement and male contraception. J. Clin. Endocrinol. Metab. 83, 4212-4219 (1998).
87. Kirby, R.S. The natural history of benign prostatic hyperplasia: What have we learned in the last decade? Urology 56, 3-6 (2000).
88. Lee, M. and Sharifi, R. Benign prostatic hyperplasia: Diagnosis and treatment guideline. Ann. Pharmacother. 31, 481-486 (1997).
89. Wilt, T., Ishani, A., and MacDonald, R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst. Rev.: CD001423 (2002).
90. Buck, A.C. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J. Urol. 172, 1792-1799 (2004).
91. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group. Prostate 22, 291-299 (1993).
92. Gormley, G.J., Stoner, E., Bruskewitz, R.C. et al. The effect of finasteride in men with benign prostatic hyperplasia. 1992. J. Urol. 167, 1102-1107 (2002).
93. Thompson, I.M., Goodman, P.J., Tangen, C.M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224 (2003).
94. Roehrborn, C.G., Boyle, P., Nickel, J.C., Hoefner, K., and Andriole, G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60, 434-441 (2002).
95. Roehrborn, C.G., Marks, L.S., Fenter, T., Freedman, S., Tuttle, J., Gittleman, M., Morrill, B., and Wolford, E.T. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63, 709-715 (2004).